Development of A MERS-CoV Replicon Cell Line for Antiviral Screening
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructe...
Gespeichert in:
| Veröffentlicht in: | Virologica Sinica 2021-08, Vol.36 (4), p.730-735 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 735 |
|---|---|
| container_issue | 4 |
| container_start_page | 730 |
| container_title | Virologica Sinica |
| container_volume | 36 |
| creator | Chen, Jing Hu, Bing-Jie Zhao, Kai Luo, Yun Lin, Hao-Feng Shi, Zheng-Li |
| description | Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the
Renilla
luciferase (
Rluc
) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV. |
| doi_str_mv | 10.1007/s12250-020-00341-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7898024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2563187604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ca085c4e2726476aa5a6584318fe4fa8f8d5990beb3303fcfe44603936f0fd9f3</originalsourceid><addsrcrecordid>eNp9kU9vVCEUxYnR2Fr9Ai4MiRs3Ty9_Hg82JpNp1SbTmLRq3BGGuYw0b2AKM5PYTy912qpduCAQ7rk_zuUQ8pLBWwYwvKuM8x464G2BkKy7fkQOmTF9pzl8f9zOapAdDMockGe1XgIoroV4Sg6EUExpIw7J8THucMzrFaYNzYFO6NnJ-UU3zd_oOa7H6HOiUxxHOosJaciFTtIm7mJxI73wBTHFtHxOngQ3Vnxxux-Rrx9Ovkw_dbPPH0-nk1nn5SA3nXegey-RD1zJQTnXO9VrKZgOKIPTQS96Y2COcyFABN9upQJhhAoQFiaII_J-z11v5ytc-Oa5-bDrEleu_LTZRftvJcUfdpl3dtBGA5cN8OYWUPLVFuvGrmL1bTyXMG-r5dJwrln70SZ9_UB6mbcltfEs71XzPCi4AfK9ypdca8Fwb4aBvQnJ7kOyDWl_h2SvW9Orv8e4b7lLpQnEXlBbKS2x_Hn7P9hfy_mcUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563187604</pqid></control><display><type>article</type><title>Development of A MERS-CoV Replicon Cell Line for Antiviral Screening</title><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Jing ; Hu, Bing-Jie ; Zhao, Kai ; Luo, Yun ; Lin, Hao-Feng ; Shi, Zheng-Li</creator><creatorcontrib>Chen, Jing ; Hu, Bing-Jie ; Zhao, Kai ; Luo, Yun ; Lin, Hao-Feng ; Shi, Zheng-Li</creatorcontrib><description>Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the
Renilla
luciferase (
Rluc
) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.</description><identifier>ISSN: 1674-0769</identifier><identifier>EISSN: 1995-820X</identifier><identifier>DOI: 10.1007/s12250-020-00341-z</identifier><identifier>PMID: 33616893</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antiviral agents ; Antiviral drugs ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Coronaviruses ; Drug discovery ; Drug screening ; High-throughput screening ; Lopinavir ; Medical Microbiology ; Microbial Genetics and Genomics ; Microbiology ; Middle East respiratory syndrome ; Oncology ; Replication ; Reporter gene ; Research Article ; Respiratory diseases ; Ritonavir ; Virology</subject><ispartof>Virologica Sinica, 2021-08, Vol.36 (4), p.730-735</ispartof><rights>Wuhan Institute of Virology, CAS 2021</rights><rights>Wuhan Institute of Virology, CAS 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ca085c4e2726476aa5a6584318fe4fa8f8d5990beb3303fcfe44603936f0fd9f3</citedby><cites>FETCH-LOGICAL-c474t-ca085c4e2726476aa5a6584318fe4fa8f8d5990beb3303fcfe44603936f0fd9f3</cites><orcidid>0000-0001-8089-163X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898024/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898024/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33616893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Hu, Bing-Jie</creatorcontrib><creatorcontrib>Zhao, Kai</creatorcontrib><creatorcontrib>Luo, Yun</creatorcontrib><creatorcontrib>Lin, Hao-Feng</creatorcontrib><creatorcontrib>Shi, Zheng-Li</creatorcontrib><title>Development of A MERS-CoV Replicon Cell Line for Antiviral Screening</title><title>Virologica Sinica</title><addtitle>Virol. Sin</addtitle><addtitle>Virol Sin</addtitle><description>Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the
Renilla
luciferase (
Rluc
) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.</description><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Coronaviruses</subject><subject>Drug discovery</subject><subject>Drug screening</subject><subject>High-throughput screening</subject><subject>Lopinavir</subject><subject>Medical Microbiology</subject><subject>Microbial Genetics and Genomics</subject><subject>Microbiology</subject><subject>Middle East respiratory syndrome</subject><subject>Oncology</subject><subject>Replication</subject><subject>Reporter gene</subject><subject>Research Article</subject><subject>Respiratory diseases</subject><subject>Ritonavir</subject><subject>Virology</subject><issn>1674-0769</issn><issn>1995-820X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU9vVCEUxYnR2Fr9Ai4MiRs3Ty9_Hg82JpNp1SbTmLRq3BGGuYw0b2AKM5PYTy912qpduCAQ7rk_zuUQ8pLBWwYwvKuM8x464G2BkKy7fkQOmTF9pzl8f9zOapAdDMockGe1XgIoroV4Sg6EUExpIw7J8THucMzrFaYNzYFO6NnJ-UU3zd_oOa7H6HOiUxxHOosJaciFTtIm7mJxI73wBTHFtHxOngQ3Vnxxux-Rrx9Ovkw_dbPPH0-nk1nn5SA3nXegey-RD1zJQTnXO9VrKZgOKIPTQS96Y2COcyFABN9upQJhhAoQFiaII_J-z11v5ytc-Oa5-bDrEleu_LTZRftvJcUfdpl3dtBGA5cN8OYWUPLVFuvGrmL1bTyXMG-r5dJwrln70SZ9_UB6mbcltfEs71XzPCi4AfK9ypdca8Fwb4aBvQnJ7kOyDWl_h2SvW9Orv8e4b7lLpQnEXlBbKS2x_Hn7P9hfy_mcUA</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Chen, Jing</creator><creator>Hu, Bing-Jie</creator><creator>Zhao, Kai</creator><creator>Luo, Yun</creator><creator>Lin, Hao-Feng</creator><creator>Shi, Zheng-Li</creator><general>Springer Singapore</general><general>KeAi Publishing Communications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8089-163X</orcidid></search><sort><creationdate>20210801</creationdate><title>Development of A MERS-CoV Replicon Cell Line for Antiviral Screening</title><author>Chen, Jing ; Hu, Bing-Jie ; Zhao, Kai ; Luo, Yun ; Lin, Hao-Feng ; Shi, Zheng-Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ca085c4e2726476aa5a6584318fe4fa8f8d5990beb3303fcfe44603936f0fd9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Coronaviruses</topic><topic>Drug discovery</topic><topic>Drug screening</topic><topic>High-throughput screening</topic><topic>Lopinavir</topic><topic>Medical Microbiology</topic><topic>Microbial Genetics and Genomics</topic><topic>Microbiology</topic><topic>Middle East respiratory syndrome</topic><topic>Oncology</topic><topic>Replication</topic><topic>Reporter gene</topic><topic>Research Article</topic><topic>Respiratory diseases</topic><topic>Ritonavir</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Hu, Bing-Jie</creatorcontrib><creatorcontrib>Zhao, Kai</creatorcontrib><creatorcontrib>Luo, Yun</creatorcontrib><creatorcontrib>Lin, Hao-Feng</creatorcontrib><creatorcontrib>Shi, Zheng-Li</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Virologica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jing</au><au>Hu, Bing-Jie</au><au>Zhao, Kai</au><au>Luo, Yun</au><au>Lin, Hao-Feng</au><au>Shi, Zheng-Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of A MERS-CoV Replicon Cell Line for Antiviral Screening</atitle><jtitle>Virologica Sinica</jtitle><stitle>Virol. Sin</stitle><addtitle>Virol Sin</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>36</volume><issue>4</issue><spage>730</spage><epage>735</epage><pages>730-735</pages><issn>1674-0769</issn><eissn>1995-820X</eissn><abstract>Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the
Renilla
luciferase (
Rluc
) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>33616893</pmid><doi>10.1007/s12250-020-00341-z</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8089-163X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1674-0769 |
| ispartof | Virologica Sinica, 2021-08, Vol.36 (4), p.730-735 |
| issn | 1674-0769 1995-820X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7898024 |
| source | Springer Nature - Complete Springer Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antiviral agents Antiviral drugs Biochemistry Biomedical and Life Sciences Biomedicine Coronaviruses Drug discovery Drug screening High-throughput screening Lopinavir Medical Microbiology Microbial Genetics and Genomics Microbiology Middle East respiratory syndrome Oncology Replication Reporter gene Research Article Respiratory diseases Ritonavir Virology |
| title | Development of A MERS-CoV Replicon Cell Line for Antiviral Screening |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T14%3A52%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20A%20MERS-CoV%20Replicon%20Cell%20Line%20for%20Antiviral%20Screening&rft.jtitle=Virologica%20Sinica&rft.au=Chen,%20Jing&rft.date=2021-08-01&rft.volume=36&rft.issue=4&rft.spage=730&rft.epage=735&rft.pages=730-735&rft.issn=1674-0769&rft.eissn=1995-820X&rft_id=info:doi/10.1007/s12250-020-00341-z&rft_dat=%3Cproquest_pubme%3E2563187604%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563187604&rft_id=info:pmid/33616893&rfr_iscdi=true |